Fibrolamellar Carcinoma — Trials

Fibrolamellar Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

21 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 11
Recruiting: 8
Ph III recruiting: 0
Growth YoY: —
Industry share: 18%
Top sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (4)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02234986	A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma	completed	Phase 2	35	CASI pharmaceuticals, Inc.INDUSTRY	1	Apr 18, 2025	clinicaltrials
NCT01642186	Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)	completed	Phase 2	28	Memorial Sloan Kettering Cancer CenterOTHER	1